Phycotoxin Purification via Segmented Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for producing and purifying phycotoxins like neosaxitoxin and saxitoxin or GTX 2 and GTX 3 on a commercial scale, limiting their availability for pharmaceutical compositions.
Innovation Solution
A continuous process involving the cultivation of cyanobacteria, cell lysis, extraction with organic solvents, purification using diatomaceous earth columns, activated charcoal, and high-performance liquid chromatography (HPLC) to achieve a definite compositional profile of phycotoxins, allowing for their use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used for phycotoxins, then the purification process is simple, but the manufacturing precision and purity are insufficient for pharmaceutical applications
Solution Approach 1:
The purification process is divided into multiple sequential stages: initial extraction with organic solvents, first HPLC purification, activated charcoal treatment, second HPLC purification, and final formulation. Each stage targets specific contaminants and progressively increases purity, transforming a single complex purification step into manageable segments that collectively achieve pharmaceutical-grade purity.
Solution Approach 2:
Activated charcoal is introduced as an intermediary substance between the extraction phase and final HPLC purification. The charcoal adsorbs specific impurities including pigments and proteins that co-elute with phycotoxins during HPLC, serving as a mediator that removes interfering substances without affecting the phycotoxin activity, thereby enabling achievement of pharmaceutical purity standards.
2Quantity of substance
If commercial-scale production of phycotoxins is attempted, then the quantity available for pharmaceutical use increases, but the current methods are inadequate for producing and purifying phycotoxins on commercial scale
Solution Approach 1:
The methodology establishes a continuous production system where cyanobacteria are cultured in large-scale photobioreactors with continuous monitoring and harvesting. The purification process operates continuously through automated HPLC systems and sequential treatment stages, maintaining consistent purity standards while producing phycotoxins at commercial scales sufficient for pharmaceutical formulation and distribution.
Solution Approach 2:
The process optimizes multiple parameters simultaneously: culture conditions (light intensity, temperature, nutrient composition) are adjusted to maximize phycotoxin yield; extraction parameters (solvent composition, pH, temperature) are optimized for efficient recovery; and purification parameters (HPLC gradient profiles, flow rates, column temperatures) are tuned to achieve pharmaceutical purity. This multi-parameter optimization enables both high quantity production and high purity maintenance.
3Stability of the object's composition
If phycotoxins are produced without controlled compositional profile, then the production process is simpler, but the definite compositional profile required for pharmaceutical compositions is not achieved
Solution Approach 1:
The system incorporates real-time monitoring of phycotoxin composition during culture and purification stages. HPLC analysis is performed at multiple points to track the compositional profile, and process parameters are adjusted based on this feedback to maintain the desired ratio of specific phycotoxins (e.g., saxitoxin and gonyautoxins). This closed-loop control ensures consistent compositional profile while maintaining production efficiency through automated monitoring and adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of phycotoxins with high purity and controlled ratios, suitable for pharmaceutical applications, including sustained release formulations, addressing the need for these compounds in pharmaceutical compositions.
Implementation Method 1
the extract purified using an organic solvent-aqueous mixture
Implementation Method 2
repeated passage through a diatomaceous earth column
Implementation Method 3
The eluate is passed through activated charcoal columns, which are washed with distilled water to remove the retained pigments and impurities
Implementation Method 4
further purified by HPLC
Data Source
AI summary
Phycotoxins are purified from a mixture of phycotoxins produced in a continuous process. Cyanobacteria are produced in a continuous culture, then lyzed, the cells pelleted and extracted, and the extract purified using an organic solvent-aqueous mixture and repeated passage through a diatomaceous earth column. The column is washed with acetic acid, then the neosaxitoxin extracted with an alcohol-water mixture. The eluate is passed through activated charcoal columns, which are washed with distilled water to remove the retained pigments and impurities, the further purified by HPLC. In one embodiment, the process produces only neosaxitoxin and saxitoxin. In another embodiment, the process produces only GTX2/3.